Neurocrine (NBIX) Stock Forecast & Price Target

Compare

1,513 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

NBIX Analyst Ratings

Strong Buy

20 Buy

2 Hold

0 Sell

Based on 22 analysts giving stock ratings to

Neurocrine

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

NBIX Stock 12 Month Forecast

Average Price Target

$179.50

▲(15.34% Upside)

Based on 22 Wall Street analysts offering 12 month price targets for Neurocrine in the last 3 months. The average price target is $179.50 with a high forecast of $203.00 and a low forecast of $146.00. The average price target represents a 15.34% change from the last price of $155.63.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"105":"$105","204":"$204","129.75":"$129.8","154.5":"$154.5","179.25":"$179.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":203,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$203.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":179.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$179.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":146,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$146.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[105,129.75,154.5,179.25,204],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,150.88,154.88923076923078,158.89846153846153,162.90769230769232,166.91692307692307,170.92615384615385,174.9353846153846,178.9446153846154,182.95384615384614,186.96307692307693,190.97230769230768,194.98153846153846,198.99076923076922,{"y":203,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,150.88,153.08153846153846,155.28307692307692,157.48461538461538,159.68615384615384,161.8876923076923,164.08923076923077,166.29076923076923,168.4923076923077,170.69384615384615,172.89538461538461,175.09692307692308,177.29846153846154,{"y":179.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,150.88,150.5046153846154,150.12923076923076,149.75384615384615,149.37846153846152,149.00307692307692,148.6276923076923,148.25230769230768,147.87692307692308,147.50153846153847,147.12615384615384,146.75076923076924,146.3753846153846,{"y":146,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":125.89,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":136.5,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":151.82,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 51,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":118.72,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":107,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":106.59,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":124.56,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":128,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 60,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":128.91,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":141.92,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 51,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":137,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":143.21,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":150.88,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$203.00

Average Price Target$179.50

Lowest Price Target$146.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Paul Matteis

Stifel Nicolaus

$183→$188

Buy

20.80%

Upside

Reiterated

12/11/25

Stifel Nicolaus Sticks to Its Buy Rating for Neurocrine (NBIX)

Brian Abrahams

RBC Capital

$160→$180

Buy

15.66%

Upside

Reiterated

12/08/25

RBC Capital Remains a Buy on Neurocrine (NBIX)

Phil Nadeau

TD Cowen

$175→$200

Buy

28.51%

Upside

Reiterated

12/05/25

Analysts Offer Insights on Healthcare Companies: Cigna (NYSE: CI), Neurocrine (NASDAQ: NBIX) and Roche Holding AG (Other OTC: RHHVF)We think there is much growth left in Ingrezza, and expect rapid adoption for Crenessity in CAH. Neurocrine is one of the few high-growth, diversified, and profitable mid-cap biotech companies. We expect NBIX to be a top performer as Ingrezza's revenue continues to increase, Crenessity's launch progresses, and NBIX's pipeline advances. Our DCF-based price target has increased from $175 to $200.

Cory Kasimov

Evercore ISI

$200

Buy

28.51%

Upside

Reiterated

11/26/25

Analysts Offer Insights on Healthcare Companies: Neurocrine (NASDAQ: NBIX) and Teva Pharmaceutical (NYSE: TEVA)

Akash Tewari

Jefferies

$169→$174

Buy

11.80%

Upside

Reiterated

11/26/25

Jefferies Reaffirms Their Buy Rating on Neurocrine (NBIX)

Sumant Kulkarni

Canaccord Genuity

$164

Buy

5.38%

Upside

Reiterated

11/26/25

Analysts Offer Insights on Healthcare Companies: Valneva (NASDAQ: VALN) and Neurocrine (NASDAQ: NBIX)

Yigal Nochomovitz

Citi

$203

Buy

30.44%

Upside

Reiterated

11/25/25

Neurocrine's Strong Market Position and Growth Potential: Buy Rating Affirmed

Andrew Fein

H.C. Wainwright

$168

Buy

7.95%

Upside

Reiterated

11/12/25

Neurocrine's Promising Prospects: Buy Rating Backed by Osavampator's Success and Ingrezza's Revenue GrowthValuation and Risks. Our price target of $168 is based on an equally weighted composite of: (a) $197.45/ share, as a 25x multiple of taxed and diluted FY26 GAAP EPS of $9 discounted back to and (b) an NPV of $139/share (discount rate 14%, growth rate 1%). Risks to our investment thesis include: (1) failure in clinical studies; (2) failure to secure regulatory approval; and (3) a smaller than anticipated commercial opportunity due to market size, competition, and/or pricing.

Sean Laaman

Morgan Stanley

$178→$173

Buy

11.16%

Upside

Reiterated

11/11/25

Neurocrine (NBIX) Gets a Buy from Morgan StanleyWe maintain the OW rating on NBIX shares as we see upside risk to Crenessity estimates.

Tazeen Ahmad

Bank of America Securities

$191

Buy

22.73%

Upside

Reiterated

11/10/25

Promising Growth Prospects for Neurocrine: Buy Rating Reaffirmed Despite SetbacksWe note no data was shared in the press release and highlight this as a likely topic of discussion for the upcoming December 16 th R&D Day. Given this was a signal seeking study, we did not model standalone value for the program and make no changes to our DCF at this time. We await additional updates on pipeline expected at the company’s R&D Day. We maintain our Buy with $191 PO as we continue to be encouraged by the company’s commercial performance for Ingrezza and Crenessity. Updates on pipeline expected on December 16 th R&D Day We highlight NBIX will be hosting an R&D Day at their headquarters in 16 th (webcast and in-person). We expect to hear updates on the company’s early-stage muscarinic portfolio including NBI-‘570 (M1/M4 agonist), NBI-‘567 (M1 agonist), NBI-‘569 (M4 agonist) and NBI-‘986 (M4 antagonist).

Ami Fadia

Needham

$184

Buy

18.23%

Upside

Reiterated

11/05/25

Analysts' Top Healthcare Picks: Seres Therapeutics (MCRB), Neurocrine (NBIX)

Anupam Rama

J.P. Morgan

$171→$179

Buy

15.02%

Upside

Reiterated

11/03/25

Neurocrine price target raised to $179 from $171 at JPMorganNeurocrine price target raised to $179 from $171 at JPMorgan

Evan Seigerman

BMO Capital

$124→$147

Hold

-5.55%

Downside

Reiterated

11/03/25

BMO Capital Sticks to Their Hold Rating for Neurocrine (NBIX)

Danielle Brill

Truist Financial

$165→$172

Buy

10.52%

Upside

Reiterated

10/30/25

Truist Financial Keeps Their Buy Rating on Neurocrine (NBIX)

Myles Minter

William Blair

―

Buy

―

Reiterated

10/29/25

Neurocrine's Strong Performance and Strategic Initiatives Drive Buy Rating

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Paul Matteis

Stifel Nicolaus

$183→$188

Buy

20.80%

Upside

Reiterated

12/11/25

Stifel Nicolaus Sticks to Its Buy Rating for Neurocrine (NBIX)

Brian Abrahams

RBC Capital

$160→$180

Buy

15.66%

Upside

Reiterated

12/08/25

RBC Capital Remains a Buy on Neurocrine (NBIX)

Phil Nadeau

TD Cowen

$175→$200

Buy

28.51%

Upside

Reiterated

12/05/25

Cory Kasimov

Evercore ISI

$200

Buy

28.51%

Upside

Reiterated

11/26/25

Analysts Offer Insights on Healthcare Companies: Neurocrine (NASDAQ: NBIX) and Teva Pharmaceutical (NYSE: TEVA)

Akash Tewari

Jefferies

$169→$174

Buy

11.80%

Upside

Reiterated

11/26/25

Jefferies Reaffirms Their Buy Rating on Neurocrine (NBIX)

Sumant Kulkarni

Canaccord Genuity

$164

Buy

5.38%

Upside

Reiterated

11/26/25

Analysts Offer Insights on Healthcare Companies: Valneva (NASDAQ: VALN) and Neurocrine (NASDAQ: NBIX)

Yigal Nochomovitz

Citi

$203

Buy

30.44%

Upside

Reiterated

11/25/25

Neurocrine's Strong Market Position and Growth Potential: Buy Rating Affirmed

Andrew Fein

H.C. Wainwright

$168

Buy

7.95%

Upside

Reiterated

11/12/25

Sean Laaman

Morgan Stanley

$178→$173

Buy

11.16%

Upside

Reiterated

11/11/25

Neurocrine (NBIX) Gets a Buy from Morgan StanleyWe maintain the OW rating on NBIX shares as we see upside risk to Crenessity estimates.

Tazeen Ahmad

Bank of America Securities

$191

Buy

22.73%

Upside

Reiterated

11/10/25

Ami Fadia

Needham

$184

Buy

18.23%

Upside

Reiterated

11/05/25

Analysts' Top Healthcare Picks: Seres Therapeutics (MCRB), Neurocrine (NBIX)

Anupam Rama

J.P. Morgan

$171→$179

Buy

15.02%

Upside

Reiterated

11/03/25

Neurocrine price target raised to $179 from $171 at JPMorganNeurocrine price target raised to $179 from $171 at JPMorgan

Evan Seigerman

BMO Capital

$124→$147

Hold

-5.55%

Downside

Reiterated

11/03/25

BMO Capital Sticks to Their Hold Rating for Neurocrine (NBIX)

Danielle Brill

Truist Financial

$165→$172

Buy

10.52%

Upside

Reiterated

10/30/25

Truist Financial Keeps Their Buy Rating on Neurocrine (NBIX)

Myles Minter

William Blair

―

Buy

―

Reiterated

10/29/25

Neurocrine's Strong Performance and Strategic Initiatives Drive Buy Rating

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Neurocrine

1 Month

xxx

Success Rate

12/17 ratings generated profit

Average Return

+2.05%

reiterated a xxx

rating 30 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 70.59% of your transactions generating a profit, with an average return of +2.05% per trade.

3 Months

xxx

Success Rate

14/17 ratings generated profit

Average Return

+6.79%

reiterated a xxx

rating 30 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 82.35% of your transactions generating a profit, with an average return of +6.79% per trade.

1 Year

Tazeen AhmadBank of America Securities

Success Rate

21/27 ratings generated profit

Average Return

+13.75%

reiterated a buy rating last month

Copying Tazeen Ahmad's trades and holding each position for 1 Year would result in 77.78% of your transactions generating a profit, with an average return of +13.75% per trade.

2 Years

xxx

Success Rate

27/27 ratings generated profit

Average Return

+24.35%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +24.35% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NBIX Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, NBIX has received 41 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. NBIX average Analyst price target in the past 3 months is 179.50.

Each month's total comprises the sum of three months' worth of ratings.

NBIX Financial Forecast

NBIX Earnings Forecast

Next quarter’s earnings estimate for NBIX is $1.86 with a range of $1.34 to $2.44. The previous quarter’s EPS was $2.04. NBIX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year NBIX has Performed in-line its overall industry.

NBIX Sales Forecast

Next quarter’s sales forecast for NBIX is $805.95M with a range of $760.80M to $830.00M. The previous quarter’s sales results were $794.90M. NBIX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year NBIX has Performed in-line its overall industry.

NBIX Stock Forecast FAQ

What is NBIX’s average 12-month price target, according to analysts?

Based on analyst ratings, Neurocrine’s 12-month average price target is 179.50.

What is NBIX’s upside potential, based on the analysts’ average price target?

Neurocrine has 15.34% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is NBIX a Buy, Sell or Hold?

Neurocrine has a consensus rating of Strong Buy which is based on 20 buy ratings, 2 hold ratings and 0 sell ratings.

What is Neurocrine’s price target?

The average price target for Neurocrine is 179.50. This is based on 22 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $203.00 ,the lowest forecast is $146.00. The average price target represents 15.34% Increase from the current price of $155.63.

What do analysts say about Neurocrine?

Neurocrine’s analyst rating consensus is a Strong Buy. This is based on the ratings of 22 Wall Streets Analysts.

How can I buy shares of NBIX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Neurocrine (NBIX) Stock Forecast & Price Target

NBIX Analyst Ratings

NBIX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Neurocrine

NBIX Analyst Recommendation Trends

NBIX Financial Forecast

NBIX Earnings Forecast

NBIX Sales Forecast

NBIX Stock Forecast FAQ

Detailed List of Analyst Forecasts